Navigation Links
Multiple in Medical Technology

Amgen Announces Positive Top-Line Results for Denosumab in Trial for Delay of Skeletal Related Events in Bone Metastases Patients Compared to Zometa(R)

... (not including breast and prostate cancer) or multiple myeloma. For the primary endpoint, ... metastasized to the bone, and to patients with multiple myeloma, both groups who routinely suffer SREs," ... cancer (excluding breast and prostate cancer) or multiple myeloma. Patients enrolled in this event-driven ...

Pharmasset Reports Positive Preliminary Antiviral Data With PSI-7851 for the Treatment of Hepatitis C

... inhibitor of HCV. PSI-7851 Phase 1 multiple Ascending Dose Study Overview In June 2009, Pharmasset initiated a phase 1 multiple ascending dose study with PSI-7851. The trial was ... dose study and HCV infected patients in the multiple ascending dose study. PSI-7851 was generally safe ...

Dirucotide Does Not Meet Primary Endpoint in Phase III MAESTRO-01 Trial in Secondary Progressive Multiple Sclerosis

... III trial in patients with secondary progressive multiple sclerosis (SPMS). In addition, there were no ... genes. It is estimated that up to 70% of all multiple sclerosis patients are HLA-DR2 and/or HLA-DR4 ... for measuring impairment in MS. About multiple Sclerosis ...

Clay Walker's Band Against MS Foundation Donates $150,000 To Support Multiple Sclerosis Research

... off big for researchers looking for a cure for multiple sclerosis. The researchers took home the top ... Pebble Beach. Wolinsky serves as director of the multiple Sclerosis Research Group and Magnetic Resonance ... who was diagnosed with relapsing-remitting multiple sclerosis in 1996. "My hope is that our support ...

More Gene Mutations Linked to Autism Risk

... the healthy controls. The complex combination of multiple genetic duplications and deletions is thought to ... of 3,832 individuals from 912 families with multiple children with ASDs from the AGRE cohort against ... said the latest findings reinforce the view that multiple gene variants, both common and rare, may be ...

Isis Highlights New Data on Antisense Drugs to Treat Type 2 Diabetes and Obesity at ADA Scientific Sessions

... significant reduction in blood glucose levels in multiple animal species. Isis and its collaborators also ... Drug, Causes Robust and Sustained Glucosuria in multiple Species and is Safe and Well-Tolerated," Dr. ... in glucose excretion in the urine in multiple species including monkeys Secondary ...

Single Port Surgeries Now Performed at University Medical Center at Princeton

... In traditional laparoscopic surgery, doctors make multiple "keyhole" incisions -- usually three or four -- ... however, still had to recover from these multiple small incisions, and deal with the cosmetic issue of multiple scars. In single port laparoscopic surgery, ...

Afinitor(R) Phase II Data Show Positive Results for Patients With Multiple Types of Lymphoma, Leading to Phase III Trial

... "We continue to see the potential of Afinitor in multiple types of cancer," said Alessandro Riva, MD, ... everolimus showed anticancer activity across multiple types of lymphoma, including T-cell non-Hodgkin's ... kidney cancer. Afinitor is being studied in multiple cancer types, including NET, breast, gastric and ...

Arena Pharmaceuticals Announces Lorcaserin Data Demonstrating Highly Significant Categorical and Absolute Weight Loss and Improvements in Secondary Endpoints Associated with Cardiovascular Risk

... improvements as compared to placebo in multiple secondary endpoints associated with ... Research Center. "Lorcaserin's positive impact on multiple secondary measures has important implications for ... significant improvements compared to placebo in multiple secondary endpoints associated with ...

Ethicon Endo-Surgery Studies Presented at DDW Demonstrate Potential of Pure NOTES Surgery With Company's Toolbox

... Ethicon Endo-Surgery, Inc. today announced that multiple studies presented at the 2009 Digestive Disease ... platform stability and adaptability to be used in multiple interventions and procedures. The surgical ... transgastrically and transvaginally completing multiple key surgical activities that included dissection, ...

Prometheus Announces New Findings Regarding Patients at Risk for Celiac Disease at DDW

... of biomarkers in patients who received multiple PROMETHEUS IBD Serology 7 tests within a two-year ... large patient cohort further confirmed that using multiple markers combined with Prometheus' Smart ... markers alone. PROMETHEUS IBD Serology 7 combines multiple serologic markers with a proprietary Smart ...

PROTECT-1 Phase II/III Induction-Stage Results for ChemoCentryx's Traficet-EN(TM) Presented in Oral Session at DDW 2009 Conference

... was consistently superior to placebo across multiple efficacy endpoints. At week 12, the CDAI greater ... platform, ChemoCentryx has internally generated multiple clinical and preclinical-stage programs, each ... to treat diseases such as Type 2 diabetes, multiple sclerosis and vascular restenosis, and CCX354, a ...

Proteolix Presents Positive Clinical Data for Carfilzomib in Multiple Myeloma at the 2009 ASCO Annual Meeting

... Rate in Phase 2 Trial of Relapsed and Refractory multiple Myeloma Patients - Proteolix Expands Trial ... survival in patients with relapsed and refractory multiple myeloma. Carfilzomib is the first in a new class ... Phase 2 clinical trial of relapsed and refractory multiple myeloma patients were presented today in an oral ...

Entremed Presents Results of ENMD-2076 Phase 1 Study in Advanced Cancer Patients

... 2. The recent initiation of Phase 1 studies in multiple myeloma and leukemia will allow us to extend the ... with a unique kinase selectivity profile and multiple mechanisms of action. Preclinical studies with ... activity, including tumor regression, in multiple solid and hematological malignancies. ENMD-2076 ...

Proteolix Presents Phase 1b/2 Clinical Data for Carfilzomib in Advanced Solid Tumor Patients at the 2009 ASCO Annual Meeting

... or metastatic solid tumors who have failed multiple prior treatments are encouraging, with a number ... the treatment benefits of carfilzomib in multiple treatment settings. We expect to complete the ... our late-stage clinical studies of carfilzomib in multiple myeloma, and we are actively planning a Phase 3 ...

Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types

... meeting. These studies provide new research on multiple tumor types and rare cancers. To view the ... + lenalidomide and dexamethasone Phase I trial in multiple myeloma (MM) In this first Phase I ... were safe when administered to patients with multiple myeloma(12). ...

Poniard Pharmaceuticals Reports First Quarter 2009 Financial Results and Provides a Corporate Update

... support its broad worldwide market potential for multiple indications beyond small cell lung cancer." ... variety of solid tumors. It is being studied in multiple cancer indications, treatment combinations and by ... in solid tumors, and is being studied in multiple cancer indications, combinations and ....

Two-Year Phase III Data Presented at AAN 61st Annual Meeting Show Positive Outcome of Cladribine Tablets in Patients With Multiple Sclerosis

... to treat patients with relapsing-remitting multiple sclerosis (MS). The results of the pivotal trial ... Tablets in this study was effective across multiple important clinical and MRI efficacy measures," ... Merck Serono. "This is an exciting development in multiple sclerosis clinical research, and represents an ...

Dendreon Presents Preclinical Data Demonstrating Activity of TRPM8 Agonist, D-3263, in Benign Prostatic Hyperplasia

... clinical trial to evaluate this molecule against multiple types of solid tumors has been recently ... It is over-expressed in prostate hyperplasia and multiple types of cancer including prostate cancer, breast ... that targets TRPM8 that could be applicable to multiple types of cancer as well as BPH. The Company has ...

Dendreon Initiates Phase 1 Clinical Trial of Small Molecule Targeting TRPM8 in Cancer

... candidate that has potential applicability to multiple types of cancer as well as to benign prostatic ... It is over-expressed in prostate hyperplasia and multiple types of cancer including prostate cancer, breast ... that targets TRPM8 that could be applicable to multiple types of cancer as well as BPH. The Company has ...

New Australian Drug Holds Hope of Major Breakthrough in Treating Terminal Blood Cancers

... from patients with a type of blood cancer called multiple myeloma, have shown that the antibody works with ... reduce the number of cancerous cells in multiple myeloma patients and improve patient health and ... has commenced a Phase 1 trial in patients with multiple myeloma and to date six patients have been ...

Surveyed Neurologists Anticipate That Less Than 30 Percent of Their Use of Emerging Oral Agents in Multiple Sclerosis Will be in the First Line

... fingolimod (FTY-720) --- for the treatment of multiple sclerosis will be in the first line. Surveyed ... The new report entitled Treatment Algorithms in multiple Sclerosis also finds that only 38.8 percent of ... of relapsing-remitting patients (the dominant multiple sclerosis subtype), they are less likely to ...

XTL Biopharmaceuticals Announces the Acquisition of the Use Patent on Recombinant Erythropoietin (rHuEPO) for the Treatment of Multiple Myeloma

... Erythropoietin ("rHuEPO") for the prolongation of multiple myeloma ("MM") patients' survival and improvement ... disease and cancer-related anemia. ABOUT multiple MYELOMA Currently incurable, MM is a ... will be developing rHuEPO for the treatment of multiple myeloma. XTL is publicly traded on the NASDAQ ...

Semafore Achieves a Preclinical Milestone with SF2626, a PI3K-MEK Dual Pathway Kinase Inhibitor

... in its CRIMP (Control Resulting from Inhibiting multiple Pathways) kinase platform by designing a small ... signaling pathway, a promising target pathway for multiple disorders, including the company's focus - ... to identify and design inhibitors that block multiple pathways. For more information see the ...

DURECT Reports Positive Phase IIb Data from TRANSDU(TM)-Sufentanil Clinical Program

... In addition, a non-clinical package comprising multiple animal safety studies has been developed, ... carcinogenicity studies, long-term toxicology and multiple biocompatibility studies. Phase IIb Trial ... and other matters, patients were randomized into multiple titration regimens. After achieving an endpoint ...

Acanya(TM) Gel, a New Treatment for Moderate to Severe Acne, Launched by Coria Laboratories

... at the initiation of acne therapy to inhibit multiple pathogenic factors. The new fixed combination, ... lives. The disorder is thought to be caused by multiple factors. Overproduction of sebum, a normal oily ... As a result, combination therapy targeting the multiple components of acne is now commonplace. In the ...

Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting

... in patients with relapsed/refractory multiple myeloma. The data, which was presented earlier today in a poster featured at the 12th International multiple Myeloma Workshop in Washington, DC, highlights a ... Patients with Relapsed or Relapsed / Refractory multiple Myeloma Who Were Previously Treated with ...

Ambrx and Merck Serono Expand Collaboration Through ARX424 Multiple Sclerosis Drug Development Alliance

... product candidate for the treatment of multiple sclerosis. ARX424 was created by Ambrx through ... harness the potential of our growth hormone and multiple sclerosis product candidates given their ... patients with cancer (Erbitux(R), cetuximab), multiple sclerosis (Rebif(R), interferon beta-1a), ...

Young Smokers Increase Risk for Multiple Sclerosis

... age 17 may increase their risk for developing multiple sclerosis (MS), according to a study released ... environmental factors play a prominent role in multiple sclerosis," said study author Joseph Finkelstein, ... disorders of the brain and nervous system such as multiple sclerosis, restless legs syndrome, Alzheimer's ...

Video: Zometa(R) Reduces Risk of Breast Cancer Recurrence in Premenopausal Women, Study in The New England Journal of Medicine Reports

... Zometa Zometa is indicated for patients with multiple myeloma and documented bone metastases from solid ... include impaired baseline renal function and multiple cycles of bisphosphonate treatment. Zometa ... ONJ based on tumor type (advanced breast cancer, multiple myeloma) and dental status (dental extraction, ...

Phase 1 Trial of Quadramet in Combination with Velcade Shows Positive Results

... for the Treatment of Relapsed or Refractory multiple Myeloma. LOS ANGELES, Feb. 11 /PRNewswire/ ... (bortezomib) is approved for the treatment of multiple myeloma alone and in addition to chemotherapy. ... Research, this US-based Phase 1 study included 39 multiple myeloma patients at three clinical oncology ....

EntreMed Presents Initial Clinical Results for ENMD-2076

... Designation from the FDA for the treatment of multiple myeloma using ENMD-2076. To further enhance its ... designation for ENMD-2076 for the treatment of multiple myeloma. The FDA accepted the Company's ... studies. A Phase 1 study with ENMD-2076 in multiple myeloma is currently underway. Orphan drug is a ...

New Study Proves Multiple Births From IVF Can Be Avoided

... Single Embryo Transfer is Effective in Reducing multiple Births. ROCKVILLE, Md., Feb. 3 ... the nation bemoan the health risk and expense of multiple births such as the octuplets born last Monday in ... when freed from financial pressures to transfer multiple embryos, which can occur when patients have ...

Inclinix Releases Next Generation Critical Population Research(R) (CPR) for Clinical Trial Investigator Site Selection and Patient Recruitment

... CPR analyzes each investigator site for multiple criteria to identify the optimal sites ... In a three-year retrospective analysis of multiple trials, Inclinix found that investigators located ... Clients benefit from ten years of experience in multiple therapeutic areas, as well as leading edge ...

Amicus Therapeutics Announces Positive Progress of Three Lead Clinical Programs and General Outlook for 2009

... Company Expects to Deliver multiple Clinical Milestones throughout the Year; Amigal ... and presented a corporate outlook consisting of multiple clinical milestones and financial guidance for ... evaluation of the safety and pharmacodynamics of multiple doses and regimens of AT2220. The results of this ...

Cylene Pharmaceuticals Initiates Phase I Trial With CX-4945 -Breakthrough First-in Class Inhibitor of CK2

... advanced solid tumors, Castleman's disease, or multiple myeloma. The primary endpoints of the oral dose ... dose for Phase II trials. In addition, multiple mechanism-related pharmacodynamic biomarkers that ... CK2 contributes to the cancer phenotype via multiple cellular events, CX-4945 has been designed with ...

Study Finds DOXIL(R) Combination Therapy Delays Disease Progression for Patients With Metastatic Breast Cancer

... is indicated for the treatment of patients with multiple myeloma who have not previously received VELCADE ... injury - In the randomized multiple myeloma study, 25 patients (8%) in the ... of DOXIL - In patients with multiple myeloma, hematologic toxicity (based on ...

Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology

... with bortezomib (+/- dexamethasone) in multiple myeloma patients relapsed from or refractory to ... in patients with relapsed/refractory multiple myeloma. The data was presented earlier today at ... Clinical Director of the Jerome Lipper multiple Myeloma Center at the Dana-Farber Cancer ...

Continued Overall Survival Advantage Reported From Pivotal Trial of VELCADE(R) (Bortezomib) for Injection Based Therapy in Patients With Previously Untreated Multiple Myeloma

... for patients with previously untreated multiple myeloma given VELCADE, melphalan and prednisone ... ) "The ultimate goal in treating multiple myeloma is to prolong the patient's life," said ... advantage for patients with previously untreated multiple myeloma." The VISTA trial enrolled 682 ...

New Study Shows PCR and FCR Have Significant Activity in B-cell Chronic Lymphocytic Leukemia

... open label-trial of Bortezomib in patients with multiple myeloma who have undergone high-dose melphalan ... Tumor Lysis Syndrome multiple Myeloma Jeffrey Matous, M.D., ... in adult patients with advanced refractory multiple myeloma Waldenstrom ...
Other Contents
(Date:7/10/2014)...  Unisys Corporation,s (NYSE: UIS ) subsidiary in ... announced that it has been selected by the Dutch Custodial ... Basic Provision Biometrics solution for penitentiaries across The ... with a solution based on its open standards-based LEIDA ... contract is up to seven years, with the new system ...
(Date:7/10/2014)... -- NXT-ID, Inc., (OTCQB: NXTD) a biometric authentication company focused on the ... was interviewed on July 1 st on the ... . Mr. Pereira discusses the company,s next generation smart wallet ... the Wocket™ aims to replace a traditional wallet with a ... tells Gino he has never heard of the Wocket ...
(Date:7/10/2014)... DUBLIN , July 3, 2014 ... the addition of the "Global Gesture Recognition ... Market - Forecasts to 2020" report to ... Global Gesture Recognition & Touch-Less Sensing ... been around for a while, but the companies ...
Breaking Biology News(10 mins):Unisys Delivers New Basic Provision Biometrics Solution to Dutch Custodial Institutions Service 2Unisys Delivers New Basic Provision Biometrics Solution to Dutch Custodial Institutions Service 3Security and Your Money: Tampa Bay Radio Host Cedric Harris Talks to NXT-ID CEO Mr. Gino Pereira about the Wocket Smart Wallet 2Security and Your Money: Tampa Bay Radio Host Cedric Harris Talks to NXT-ID CEO Mr. Gino Pereira about the Wocket Smart Wallet 3Security and Your Money: Tampa Bay Radio Host Cedric Harris Talks to NXT-ID CEO Mr. Gino Pereira about the Wocket Smart Wallet 4Global Gesture Recognition & Touch-Less Sensing (2D, 3D, Ultrasonic, IR, Capacitive) Market - Forecasts to 2020 2
(Date:7/11/2014)... enterprises today are shifting towards the changing trend in ... offer these global enterprises a strategic method to cut ... operational costs to companies. The aim to minimize operational ... market driver for expanding the managed services market in ... estimated to grow from $142.75 billion in 2013 to ...
(Date:7/11/2014)... 11, 2014 As reported by the ... (Weintraub 7/11/14), a significant number of severe adverse events ... issues and even death from the highly-promoted and costly ... the Times report , a regulatory filing revealed ... by patients was almost 14% of prescriptions, up from ...
(Date:7/11/2014)... Wash.The largest study of its kind has found ... of advantages over their conventional counterparts, including more ... The study looked at an unprecedented 343 peer-reviewed ... organic and conventional plant-based foods, including fruits, vegetables, ... techniques to quantify differences between organic and non-organic ...
(Date:7/11/2014)... Steven Reinberg HealthDay ... A potential vaccine to protect children from the worldwide scourge ... Asian children. While the vaccine only prevented dengue fever ... full series of three shots, it protected more than 88 ... dengue fever can lead to hospitalization, and sometimes death. ...
(Date:7/11/2014)... Ticket Down is a reliable source for cheap ... in Wheatland, CA. In the Sacramento California area there ... Train Amphitheatre can do for music fans. The venue has ... of its existence and can seat 18,500 fans each night. ... metro area) will host the “That’s My Kind of Night” ...
Breaking Medicine News(10 mins):Health News:North America Managed Services Market Worth $68.65 Billion by 2018 - New Report by MicroMarket Monitor 2Health News:North America Managed Services Market Worth $68.65 Billion by 2018 - New Report by MicroMarket Monitor 3Health News:North America Managed Services Market Worth $68.65 Billion by 2018 - New Report by MicroMarket Monitor 4Health News:Acthar’s Deadly Adverse Events Revealed 2Health News:Acthar’s Deadly Adverse Events Revealed 3Health News:Major study documents nutritional and food safety benefits of organic farming 2Health News:Major study documents nutritional and food safety benefits of organic farming 3Health News:Dengue Fever Vaccine Shows Some Promise in Trial 2Health News:Dengue Fever Vaccine Shows Some Promise in Trial 3Health News:Luke Bryan Tickets Sleep Train Amphitheatre in Wheatland, CA (Sacramento): Ticket Down has Slashed Ticket Prices on Luke Bryan in Wheatland at Sleep Train 2Health News:Luke Bryan Tickets Sleep Train Amphitheatre in Wheatland, CA (Sacramento): Ticket Down has Slashed Ticket Prices on Luke Bryan in Wheatland at Sleep Train 3
Other TagsOther Tags